Clinical Trial

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with chemotherapy in patients with recurrent or advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-27; most recent amendment 2024-01-20.
Trial Details
NCT Number NCT06066216
Lead Sponsor Fujian Cancer Hospital
Collaborators: Fujian Provincial Hospital, The First Affiliated Hospital of Nanchang University, Zhangzhou Affiliated Hospital of Fujian Medical University, The First Affiliated Hospital of Bengbu Medical University
Conditions Endometrial Cancer, Endometrial Adenocarcinoma
Enrollment 45 participants
Start Date 2024-02-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-23